The latest research report on T-Cell Therapy Market delivers a comprehensive study on current market trends. The outcome also includes revenue forecasts, statistics, market valuations which illustrate its growth trends and competitive landscape as well as the key players in the business.
T-Cell Therapy Market Size
Global T-Cell Therapy Market is valued at USD 5432.1 Billion in 2020 and expected to reach USD 19126.1 Billion by 2027 with the CAGR of 19.7% over the forecast period.
Get Sample Copy of This Premium Report @ https://brandessenceresearch.com/requestSample/PostId/1553
Scope of T-Cell Therapy Market
T-cells play an important role in immunity to foreign substances. T cells, also called T lymphocytes, are a type of leukocyte (white blood cell) that is an essential part of the immune system. T cells are part of the immune system that focuses on specific foreign particles. Rather than normally attacking any of the antigens, T cells transmit until they meet their specific antibiotic cells – another type of lymphocyte B cells that determines the specificity of antigenic immunity in the body. The most common reference to T cells is in infectious diseases, but they are also used for other aspects of adaptive immunity. This includes all allergens and tumor responses. They maintain immune homeostasis in humans for decades but can also cause inflammatory or autoimmune diseases. Additionally, In 2002, The MSK team makes the first effective CART cells targeted against prostate cancer antigen. These second-generation CAR T cells are capable of sustaining, transmitting, and killing progressive cancer cells in the laboratory, establishing the feasibility of CAR T cell therapy.
The COVID-19 pandemic has impacted all areas of daily life, including the healthcare globally. Especially, delivering care for patients with cancer or suspected cancer during this crisis has been very challenging given the competing risks of death from untreated or undertreated cancer versus death or serious complications from SARS-CoV-2, and the likely higher lethality of COVID-19 in immunocompromised hosts. Many patients with cancer have struggled to receive treatment for their cancers due to hospitals canceling or delaying surgeries and other procedures, including chemotherapy and radiation therapy. Thus, all these factors have shown a decline impact on the T-cell therapy market. However, a group of researchers sought to examine the potential of targeting COVID-19 using off-the-shelf T cells that recognized SARS-CoV-2 may create more opportunities for the market growth.
The global T-cell therapy market report is segmented on the basis of modality, therapy type, indication and regional & country level. Based on type, global T-cell therapy market is classified into research and commercialized. Based on therapy type, global T-cell therapy market is classified into CAR T-cell Therapy, T Cell Receptor (TCR)-based and Tumor Infiltrating Lymphocytes (TIL)-based. Based on indication, global T-cell therapy market is classified into hematologic malignancies and solid tumors. The hematologic malignancies is sub segmented into lymphoma, leukemia and myeloma and solid tumor is sub segmented into melanoma, brain & central nervous system, liver cancer and others. Based on end-user, the market is classified into hospitals, cancer treatment center and others.
Global T-cell therapy Market Segmentation:
By Therapy Type:
- CAR T-cell Therapy
- T Cell Receptor (TCR)-based
- Tumor Infiltrating Lymphocytes (TIL)-based
- Solid Tumor
- brain & central nervous system
- liver cancer
- Cancer Treatment Centers
The regions covered in this Global T-cell therapy market report are North America, Europe, Asia-Pacific, and the Rest of the World. Based on the country level, the market of T-cell therapy is sub divided into U.S., Mexico, Canada, UK, France, Germany, Italy, China, Japan, India, South East Asia, GCC, Africa, etc.
Request for Methodology @ https://brandessenceresearch.com/requestMethodology/PostId/1553
T-Cell Therapy Companies
Global T-cell therapy market report covers prominent players are like Key players in the market include
- Novartis AG
- Merck KGaA
- Gilead Sciences Inc.
- TCR2 Therapeutics Inc
- Bluebird Bio Inc.
- Sorrento Therapeutics
- Fate Therapeutics
- Pfizer Inc.,
- Celgene Corporation
T-Cell Therapy News
FDA Approved New CAR-T Therapy for Multiple Myeloma
April 1ST, 2021; the Food and Drug Administration (FDA) approved Abecma (idecabtagene vicleucel, or ide-cel), a new CAR-T therapy for adults with relapsed or refractory (nonresponsive) multiple myeloma who have tried at four previous lines of therapy. Abecma is the first FDA-approved CAR-T therapy for multiple myeloma. Abecma is a “living drug” that reprograms a patient’s own T cells to fight cancer.
Chimeric antigen receptor T-cell therapy, better known as CAR-T involves removing a sample of a patient’s white blood cells, genetically modifying the T cells to recognize and attack their cancer, manufacturing a large number of the modified cells and infusing them back into the body. Abecma (formerly known as bb2121) was initially discovered by bluebird bio and was jointly developed with Bristol-Myers Squibb (BMS).
Global T-Cell Therapy Market Dynamics
The rising incidences of cancer is one of the major factors driving the growth of growth of the T-cell therapy market. For example, according to the national cancer institute, the rate of new cases of leukemia was 14.3 per 100,000 men and women per year. The death rate was 6.3 per 100,000 men and women per year.
Whereas, various types of cancer treatment are available but chemo and radiation, which kill healthy cells as well as cancerous ones, immunotherapy targets the tumors with more precision. Due to this and CAR T cell therapy is only used in blood cancer so the demand for this therapy is increasing eventually. And, as per the World Health Organization (WHO), cancer is second major causes for mortality around the world, representing an expected 10 million deaths every year. In 2018, 18.1 million individuals around the globe had cancer, and 9.6 million died from the diseases.
Additionally, increasing number of FDA approvals for the products in this market are also supplementing the market growth. Moreover, due to the increasing effectiveness of these therapies, FDA approved various T-cell therapies. For example, The FDA approved the first CAR T-cell therapy in 2017 Axicabtagene ciloleucel and Tisagenlecleucel. Tisagenlecleucel has the same approval as Axicabtagene ciloleucel but it also can be used to treat children and young adults with acute lymphoblastic leukemia. According to the National Cancer Institute, more than 50 percent of all new cases occur in patients younger than 20 from Tisagenlecleucel treatment because is approved as a treatment option for acute lymphoblastic leukemia (ALL) in patients 25 and younger who have recurrent cancer or whose disease is resistant to treatment. Axicabtagene ciloleucel Adult patients with large B-cell non-Hodgkin lymphoma have been approved as a treatment option, and if their cancer has returned or their disease has not responded after the other two types of treatment. Furthermore, growing awareness regarding the T-cell therapy and growing number of supportive initiatives taken by governments are also supplementing the market growth.
However, the high cost of T-cell therapy and its side effects may hamper market growth. In spite of that, increasing investment in research and development to develop more innovative offerings in this market will create more opportunities for the further growth of the market.
Complete Report Details @ https://brandessenceresearch.com/healthcare/t-cell-therapy-market
North America is Expected to Dominate the Global T-Cell Therapy Market
The global T-cell therapy market is segmented into North America, Europe, Asia-Pacific Latin America and Middle East & Africa. North America is expected to dominate the global T-cell therapy market within the forecast period owing to the increasing number of cancer cases and growing awareness regarding the T cell therapy in this region. For example, Leukemia affects both children and adults, and 10% of new cancers occur in the United States each year. That means about 178,520 people have been diagnosed with leukemia this year. Of these, 34% will be diagnosed with leukemia, 48% with lymphoma, and 18% with myeloma. Additionally, the presence of technologically advanced pharmaceutical companies and cancer research centers are some of the major factors supplementing the market growth in this region.
Additionally, Asia Pacific is expected to witness a significant growth owing to the increasing awareness about T cell therapy and growing investment in this field. For example, Novartis announced that Singapore Health Sciences Authority (HSA) has approved Kymriah (tisagenlecleucel) as the first commercial chimeric antigen receptor T-cell (CAR-T) therapy in Singapore under the new cell, tissue and gene therapy products (CTGTP) regulatory framework.
Key Benefits for Global T-cell therapy Market Report–
- Global T-cell therapy market trends report covers in depth historical and forecast analysis.
- Global T-cell therapy industry statistics research report provides detail information about Market Introduction, Market Summary, Global market Revenue (Revenue USD), Market Drivers, Market Restraints, Market opportunities, Competitive Analysis, Regional and Country Level.
- Global T-cell therapy industry analysis report helps to identify opportunities in market place.
- Global T-cell therapy market trends report covers extensive analysis of emerging trends and competitive landscape.
By Regional & Country Analysis: (North America, U.S., Canada, Europe, U.K., France, Germany, Italy,Asia Pacific, China, Japan, India, Southeast Asia, Latin America, Brazil, Mexico, Middle East and Africa, GCC, Africa, Rest of Middle East and Africa)
Table of Content
1. Chapter – Report Methodology
1.1. Research Process
1.2. Primary Research
1.3. Secondary Research
1.4. Market Size Estimates
1.5. Data Triangulation
1.6. Forecast Model
1.7. USP’s of Report
1.8. Report Description
2. Chapter – Global T-Cell Therapy Market Overview: Qualitative Analysis
2.1. Market Introduction
2.2. Executive Summary
2.3. Global T-Cell Therapy Market Classification
2.4. Market Drivers
2.5. Market Restraints
2.6. Market Opportunity
2.7. T-Cell Therapy Market: Trends
2.8. Porter’s Five Forces Analysis
2.9. Market Attractiveness Analysis
3. Chapter – Global T-Cell Therapy Market Overview: Quantitative Analysis
4. Chapter – Global T-Cell Therapy Market Analysis: Segmentation By Type
5. Chapter – Global T-Cell Therapy Market Analysis: Segmentation By Application
About Us: Brandessence Market Research and Consulting Pvt. ltd.
Brandessence market research publishes market research reports & business insights produced by highly qualified and experienced industry analysts. Our research reports are available in a wide range of industry verticals including aviation, food & beverage, healthcare, ICT, Construction, Chemicals and lot more. Brand Essence Market Research report will be best fit for senior executives, business development managers, marketing managers, consultants, CEOs, CIOs, COOs, and Directors, governments, agencies, organizations and Ph.D. Students. We have a delivery center in Pune, India and our sales office is in London.
Contact us at: +44-2038074155 or mail us at firstname.lastname@example.org